Physician profile
Binbin Yi
NPI 1619592466
$2,678.20
in general payments reported to CMS, 2019-2025
23 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $118 · 2023: $487 · 2024: $684 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.80 |
| Education | $134.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $350.54 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $345.05 | 2021-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $293.92 | 2024-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $241.45 | 2024-2025 | Tremfya, Simponi, Stelara |
| Ardelyx, INC. | $218.32 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $179.28 | 2023-2025 | Dupixent |
| Abbvie INC. | $174.54 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $150.47 | 2022-2024 | |
| Qol Medical, LLC | $126.86 | 2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $110.73 | 2023 | |
| Baxter Healthcare | $103.90 | 2025 | Tisseel |
| E.R. Squibb & Sons, L.L.C. | $82.74 | 2021 | |
| Madrigal Pharmaceuticals | $71.85 | 2025 | Rezdiffra |
| Celgene Corporation | $42.59 | 2024 | Zeposia |
| Celltrion USA INC. | $39.93 | 2024 | Zymfentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.38 | 2024 | |
| Exact Sciences Corporation | $21.70 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $21.53 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.16 | 2025 | Relistor |
| Vivus LLC | $18.58 | 2025 | Pancreaze |
| Mirum Pharmaceuticals, INC. | $16.65 | 2025 | Cholbam, Livmarli, Chenodal |
| Shield Therapeutics INC | $13.55 | 2025 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binbin Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.